Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
380.90
-11.10 (-2.83%)
Nov 24, 2025, 4:00 PM EST
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B CHF
Revenue Growth
+4.80%
P/S Ratio
4.12
Revenue / Employee
614.90K CHF
Employees
103,249
Market Cap
329.10B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Tian'an Technology Group | 2.12M |
Roche Holding AG News
- 5 days ago - Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution - Seeking Alpha
- 5 days ago - KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors - Business Wire
- 6 days ago - Roche: European Commission Grants Conditional Marketing Authorisation Of Lunsumio - Nasdaq
- 6 days ago - European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma - GlobeNewsWire
- 6 days ago - Market bubbles cracking: Gold & defense stocks the go‑to strategy, says David Roche - CNBC
- 6 days ago - Why biotech and drug stocks are on the mend even though the rest of the market is hurting - Market Watch
- 6 days ago - RHHBY Reports Positive Phase III Data on Breast Cancer Drug - Nasdaq
- 6 days ago - Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock - Benzinga